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Societal Impact Statement
Plants are living repositories of pharmacologically active chemicals and help to meet 
society's health care needs directly, or by providing natural products for drug devel-
opment. We describe phylogenetic approaches to compare medicinal floras from dif-
ferent cultures in distinct regions of the world, and consider how these findings can 
improve knowledge of how plants have been selected for medical purposes. Greater 
insight into how people have selected plants for medicinal use will benefit health-
care and drug discovery strategies, and ultimately contribute to the future health and 
well-being of society.
Summary 
• Four medicinal floras were compared using phylogenetic methods, to test whether 
there are shared patterns in medical plant use at the level of the whole medicinal 
floras, or for specific therapeutic applications.
• Checklists of the native plants and medicinal plants of Oman were compiled, and 
analyzed alongside existing checklists for Nepal, the Cape of South Africa and 
New Zealand. We reconstructed a plant phylogeny at generic level for Oman, and 
a new, more inclusive phylogeny to represent the genera found in all four local 
floras. Methods from community phylogenetics were used to identify clustering 
and overdispersion of the plants used. The impacts of using local or more inclusive 
phylogenies and different null model selections were explored.
• We found that Omani medicinal plant use emphasizes the same deep lineages of 
flowering plants as the other three medicinal floras, most strongly when compar-
ing Omani and Nepalese medicinal plants. Drivers of this similarity might be flo-
ristic composition, opportunity for exchange of knowledge and shared beliefs in 
the causation of illness. Phylogenetic patterns among therapeutic applications are 
cross-predictive within and between cultures, and must be interpreted with care 
since inappropriate use of null models can result in spurious similarity. High levels 
of cross-predictivity suggest that targeting plants used for specific therapeutic 
applications to identify specific bioactives may have limited value.
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1  | INTRODUC TION
The plants used for medicine, referred to as the medicinal flora 
of a culture (Ellen & Puri, 2016; Moerman, Pemberton, Kiefer, & 
Berlin, 1999), or sometimes as its plant ethnopharmacopoeia (Cox, 
Sperry, Touminen, & Bohlin, 1989; Saslis-Lagoudakis et al., 2012), 
are documented in the scientific literature by ethnobotanists. 
Ethnobotanical research has entered a phase of hypothesis test-
ing using this body of published data (Albuquerque & Muniz de 
Medeiros, 2012; Gaoue et al., 2017). Whether there is a “global 
pattern of human knowledge” (Moerman et al., 1999) is one ques-
tion posed by ethnobotanists and ethnopharmacologists, and 
relevant to healthcare practice and policy, and to bioprospect-
ing (Albuquerque & Muniz de Medeiros, 2012; Saslis-Lagoudakis 
et al., 2012; Waldstein & Adams, 2006). Although there has been 
no global study to date, it is known that selection of plants for 
medicine is not random: some plant families are preferred (Leonti 
et al., 2013; Moerman, 1979, 1991). People of different ethnolin-
guistic cultural groups (cultures hereafter) may prefer the same 
families (Moerman, 1979, 1991; Saslis-Lagoudakis, Williamson, 
Savolainen, & Hawkins, 2011; Weckerle, Cabras, Castellanos, & 
Leonti, 2011), but not always (Ford & Gaoue, 2017). Shared pat-
terns might be attributed to common selection criteria (Leonti, 
Ramirez, Sticher, & Heinrich, 2003), independent discovery of ef-
ficacy (Saslis-Lagoudakis et al., 2012) or transmission of knowl-
edge (Hawkins & Teixidor-Toneu, 2017; Teixidor-Toneu, Jordan, & 
Hawkins, 2018). Differences could reflect adaptations to different 
floristic environments, or different healthcare practices, health 
needs or belief systems. The explanations of common patterns, or 
of deviations from them, are relevant to healthcare and drug dis-
covery (Teixidor-Toneu et al., 2018).
Phylogenetic approaches offer insights distinct from the 
widely used taxon-based cross-cultural investigations. In one ap-
plication, phylogenetic approaches are able to identify and quan-
tify shared preferences for plants overall (Saslis-Lagoudakis et al., 
2014; Teixidor-Toneu et al., 2018; Thompson et al., unpublished). In 
cross-cultural studies such as these, metrics describe the related-
ness of pairs of medicinal floras, rather than the component lineages, 
families or genera; the relatedness of the medicinal floras can be 
used as the comparative basis for identifying drivers of overall simi-
larity in medicinal floras. For example, when relatedness of floristic 
environment is significantly correlated with relatedness of medicinal 
floras, this suggests adaptation to the floristic environment is driving 
medicinal plant selection (Saslis-Lagoudakis et al., 2014). However, 
other studies have shown a significant effect of cultural ancestry 
(Thompson et al., unpublished).
Although phylogenetic methods are a powerful tool to explore 
global patterns in medicinal plant use, the scope of this approach is still 
poorly understood. For instance, there are no accounts yet that ex-
plore the outcomes of adding further local floras and medicinal floras 
to an existing phylogenetic analysis of three floras (Saslis-Lagoudakis 
et al., 2012). This study was among the first to use community phy-
logenetic tools to explore patterns of medicinally used plants. Saslis-
Lagoudakis et al. (2012) revealed clustering of medicinal floras within 
the floras they were drawn from. They also revealed shared phylo-
genetic patterns across the floras: medicinal floras were more closely 
related than would be expected if there were not shared preferences. 
The finding was taken to indicate independent discovery of plant ef-
ficacy, an interpretation supported by significant over-representation 
of proven bioactive species in shared lineages. In the present study, we 
compare the medicinal flora of Oman to those of three medicinal floras 
contrasted in the previous study by Saslis-Lagoudakis et al. (2012), the 
medicinal floras of New Zealand, South Africa and Nepal. These four 
represent different ecoregions. Oman, located in the Southeast of the 
Arabian Peninsula at the meeting point between Africa and Asia, has 
over 1,200 vascular plant species over half of which are annuals, flow-
ering irregularly from year to year according to the timing and amount 
of rain (Ghazanfar, 2003). Mountainous areas are especially diverse 
floristically and include endemic species (around 5% of the species in 
Dhofar, southern mountains; Ghazanfar, 2003). New Zealand com-
prises an archipelago of three main islands in the southern Pacific 
Ocean, and has a flora of approximately 1900 species, 45% of which 
are endemic (Wilton & Breitwieser, 2010). The Cape of South Africa, 
located at the south and south-eastern tip of Africa has over 9,000 spe-
cies of which 70% are endemic (Goldblatt & Manning, 2002). The flora 
of Nepal, a country spanning from lowland plains (Terai) to the highest 
Himalayan peaks, is estimated to have between 6,000 and 6,600 spe-
cies of flowering plants (Press, Shrestha, Sutton, & Carneiro, 2000), of 
which around 4% are endemic (Shrestha & Joshi, 1996).
The medical tradition of Arabic regions is a pluralistic system that 
includes Prophetic medicine, concerned with spirit aetiologies, and 
Galenic humoral medicinal, concerned with environmental factors 
(Greenwood, 1981). The Galenic humoral system or "Unani tibb" un-
derlies traditional medicine in northern and central Oman (Ghazanfar 
& Al-Sabahi, 1993) and is also part of the pluralistic medical system in 
southern Oman (Miller & Morris, 1988). Knowledge about herbal med-
icines in Oman is not traditionally written down but is passed orally 
from one generation to the next (Ghazanfar & Al-Sabahi, 1993). Until 
• We outline the questions that might be addressed using a global phylogeny and 
medicinal plant checklists, suggest the best methods for future studies and pro-
pose how findings might be interpreted.
K E Y W O R D S
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recently, traditional medicine was the only available healthcare strat-
egy in Oman (Ghazanfar, 1994; Ghazanfar & Al-Sabahi, 1993), but 
treatments using traditional medicines have become less popular in the 
past two decades because of the establishment of hospitals. However, 
minor ailments such as headaches, colds, fever, and stomach upsets, are 
still treated using medicinal plants (Ghazanfar & Al-Sabahi, 1993). Nepal 
is a mosaic of cultures with over 75 ethnolinguistic groups (mainly of 
Tibetan-Burman or Indio-European origin), resulting in diverse health-
care strategies (Gaenszle, Turin, Tuladhar-Douglas, & Chhetri, 2015). As 
in Oman, in Nepal scholarly, written medical systems are used along-
side oral folk medicine. Unani medicine is one of these scholarly medi-
cines, together with the more popular Ayurveda and Tibetan medicine 
(Gewali, 2008). Moreover, in Nepal shamanistic medicine is practiced 
when a person's illness is believed to be caused by a spirit possession 
(Gewali, 2008). Formal, written medical systems were not traditionally 
used in New Zealand or the Cape South Africa. The native people of 
New Zealand, the Māori, are of Polynesian origin and had developed 
an independent ethnopharmacopoeia due to their isolation between 
settlement (around 1,300 S.D; Wilmshurst, Anderson, Higham, & 
Worthy, 2008) and European colonization (18th century). Since contact 
with Europeans it is likely that their medical system was influenced by 
newcomers, but the precolonial medicinal flora is well documented. The 
Cape of South Africa is populated by various ethnic groups, but accord-
ing to Kale (1995), their traditional medicine is essentially similar and 
based on supernatural belief. Different traditional healers play a key 
role: “isangomas” are mostly female spiritual healers that also address 
social causes of illness and “inyangas” are mostly male and use herbs 
and medicines to treat people (South African History Online, 2018).
The primary objective of this study is to determine whether the 
medicinal plants of Oman, (a) overall and (b) for specific therapeu-
tic applications, are more closely related to those of New Zealand, 
the Cape of South Africa and Nepal than expected by chance. The 
floras of New Zealand, the Cape of South Africa and Nepal were 
selected for the original study to represent cultures with negligible 
pre-colonial contact (Saslis-Lagoudakis et al., 2012). By introducing 
Oman, patterns of putatively shared knowledge across disparate 
floras but culturally connected people are characterized for the first 
time. A further objective is to consider the questions that might be 
addressed by a global phylogenetic survey, and to outline methods 
appropriate to address these questions.
2  | MATERIAL S AND METHODS
2.1 | Data collection
A checklist list of the plant species of Oman was compiled from the 
four volumes of the Flora of Oman (Ghazanfar, 2003, 2015, 2018; 
Ghazanfar & Patzelt, 2007; Kearse et al., 2012). As in other cross-
cultural studies (i.e., Moerman et al., 1999), our checklist only in-
cludes angiosperms because gymnosperm data were not readily 
available. A checklist of the native medicinal species of Oman was 
compiled from the medicinal flora of northern Oman (Ghazanfar & 
Al-Sabahi, 1993) and the medicinal flora of southern Oman (Miller 
& Morris, 1988). The applications of medicinal plants were classi-
fied into 12 therapeutic applications (gastro-intestinal, general, gy-
naecology/fertility, dentistry/mouth, musculoskeletal, neurology, 
ophthalmology, otorhinolaryngology, other, respiratory/pulmonary, 
skin, and urinary) following Saslis-Lagoudakis et al. (2012) and others 
cited therein. The cardiovascular/blood purity therapeutic applica-
tion included in the study of Saslis-Lagoudakis et al., (2012) was not 
represented among the applications of the native Omani medicinal 
flora and was not included further.
Floristic checklists and medicinal floras for Nepal, New Zealand, 
and the Cape of South Africa were sourced from Saslis-Lagoudakis 
et al., (2012). The number of genera shared between Oman and each 
of the other three floras, and between the Omani medicinal floras 
and each of the other three medicinal floras were recorded.
2.2 | DNA sequences and phylogenetic 
reconstruction
A phylogeny for the Omani flora was reconstructed at the genus level, 
following Saslis-Lagoudakis et al., (2012). A list of the 452 genera 
present in Oman was prepared and a single exemplar rbcL sequence 
downloaded from Genbank for each genus using the Geneious soft-
ware (Kearse et al., 2012). The plastid DNA marker rbcL was used 
because of the availability of data for this marker, its successful am-
plification among plant lineages, and its ability to resolve phyloge-
netic relationships in large-scale studies (Chase et al., 1993; Forest 
et al., 2007; Savolainen et al., 2000) . Where possible, we selected 
a species present in the Omani flora, but in cases where a DNA se-
quence for Omani species was not available, a Saudi Arabian or other 
species was selected; 361 exemplar sequences were downloaded 
from Genbank, therefore we compiled genetic data for ∼80% of the 
genera present in the flora. When the Genbank names did not corre-
spond to those in the flora of Oman, a recognized synonym from the 
Plant List (The Plant List, 2013) was used. Outgroup sampling com-
prised the following 16 species (as in Saslis-Lagoudakis et al., 2012): 
Abies homolepis, Araucaria bidwillii, Cedrus deodara, Cryptomeria ja-
ponica, Cupressus sempervirens, Cycas circinalis, Ephedra gerardiana, 
Ginkgo biloba, Gnetum montanum, Juniperus communis, Larix occiden-
talis, Picea smithiana, Pinus wallichiana, Podocarpus neriifolius, Taxus 
wallichiana and Tsuga dumosa. Alignment of the rbcL sequences was 
performed in BioEdit v. 7.0 using CLUSTAL W (Hall, 1999) and ad-
justments were made manually. A phylogenetic tree of relationships 
of Oman flora was reconstructed under maximum likelihood crite-
rion using RAxML (Stamatakis, Hoover, & Rougemont, 2008).
Data for the reconstruction of a combined phylogeny including 
the floras of the Cape of South Africa, Nepal and New Zealand 
were those used by Saslis-Lagoudakis et al. (2012). The sequence 
alignments were combined with the Omani sequences to con-
struct a phylogenetic tree representing genus-level plant relation-
ships among all four floras. For this analysis, when a genus was 
present in more than one flora it was included only once in the 
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analysis. The alignment of the combined matrix was performed 
in MAFFT v.7 (Katoh, 2013) with manual adjustments perfomed 
in BioEdit v. 7.0 (Hall, 1999). Sequence data were analyzed under 
the maximum-likelihood (ML) criterion implemented in RAxML 
(Stamatakis et al., 2008). Rate smoothing was implemented in 
the ape package (Paradis, Claude, & Strimmer, 2004), using the 
chronoMPL function. This model-free method applies the mean 
path length for each node to all descendants for dating (Britton, 
Oxelman, Vinnersten, & Bremer, 2002). Where this method in-
troduces very short negative branches, they were converted to 
zero-length branches.
2.3 | Data analysis
PHYLOCOM version 4.2 (Webb, Ackerly, & Kembel, 2008) was used 
for phylogenetic interpretation. To run an analysis, a phylogeny writ-
ten in Newick format and a sample file are needed. For ecological ap-
plications, the sample files typically describe presence or absence of 
taxa in different communities. In our work, the sample files can de-
scribe different categories, such as presence or absence of a genus 
in a local flora, presence or absence of the medicinal use of a genus, 
or presence or absence of use of genera for specified therapeutic 
applications.
Three functions in PHYLOCOM, comstruct, comdist, and com-
distnt, were employed to calculate two phylogenetic metrics, mean 
phylogenetic distance (MPD) and mean nearest taxon distance 
(MNTD). Comstruct is used to test whether a category specified by 
a sample file has phylogenetic structure. Comdist and Comdistnt are 
used to test for phylogenetic relatedness between categories speci-
fied by a sample file, either at deep (Comdist) or shallow (Comdistnt) 
levels. In general, MNTD is influenced by patterns near the tips, 
whilst MPD is informative of phylogenetic structure deeper in the 
phylogeny. Net Relatedness Index (NRI) and Nearest Taxon Index 
(NTI) are the standardized effect size (z-scores) of MPD and MNTD 
respectively according to the equations described in PHYLOCOM 
user's manual 4.2:
In these equations, MPDrandom and MNTDrandom represent values 
calculated for null communities, where null communities are random 
samples. Sampling to generate the null communities can be imple-
mented in different ways, according to different null models. There 
are two null models that we use here (Table 1). For example, under 
null 0 which samples any plant in the phylogeny to make a null com-
munity, and where the phylogeny only comprises genera in the local 
flora, comstruct analysis can be used to test whether medicinal genera 
(a category in the sample file) are a phylogenetically structured subset 
of plants in the local flora. If the phylogeny includes genera that are 
not in the local flora, the same question can be asked if the sample file 
specifies plant genera in the local community as a category. This is be-
cause, under null model 1 the null community is sampled from genera 
that appear in any category in the sample file (Figure 1).
In these analyses, NRI and NTI values are outputs along with 
their rankLow and rankHigh values. The rankLow/High values de-
scribe the number of actual comparisons for which the observed dis-
tance in the sample is shorter/longer than the null community. From 
rankLow/High values, two-tailed p-values are calculated. Positive 
NRI/NTI values represent phylogenetic clustering, negative values 
indicate phylogenetic over-dispersion. NTI or NRI values > 1.96 or 
<−1.96 are considered significant at an alpha threshold of p < .05 
(in a two-tailed p test, corresponding to p < .025 and p > .975 
respectively).
Here, we carry out six tests; their purpose and the metric and 
function, phylogeny and null model are described in full in Table 1. 
Tests 1 and 2 have equivalent aims. In both cases the analysis sets 
out to determine whether the medicinal flora (in this case the me-
dicinal genera of Oman) is clustered relative to the local flora (in 
this case the generic-level flora of Oman). In the first test the local 
flora is delimited by the phylogeny. In other words, the sequences 
used to reconstruct the phylogeny represent only the genera from 
the local flora. Therefore, a null model that draws from the whole 
phylogeny to make a null community is used (equivalent to null 
model 0 in Phylocom; Webb et al., 2008). In the second test, the 
phylogeny included genera that are not in the local flora. Therefore, 
the sample file must be used to delimit the local flora and the me-
dicinal flora, and the null community is drawn from the local flora 
by specifying a null model that will draw the null community from 
the sample file. This is Phylocom's null model 1, specifically “for 
each sample, species are drawn without replacement from the list 
of all species actually occurring in at least one sample" (page 20, 
Webb, Ackerly, & Kembel, 2011). Figure 1 explains the relationship 
between null models and sample files for local and combined phy-
logenies. Comparison of tests 1 and 2 can be made to determine 
the influence of a phylogeny built to represent a local flora, and 
one that is more inclusive.
Tests 3 to 6 depend on measures of inter-sample phylogenetic 
distances, where the samples are the whole medicinal floras, 
or the subset of the medicinal flora with specific therapeutic 
applications (Table 1). For tests 3 to 6, all four local floras are 
represented in the phylogeny. The aim of test 3 is to determine 
whether the whole medicinal flora of Oman is drawn from the 
same deep lineages as the medicinal floras of other areas. Tests 
4, 5, and 6 are different methods of investigating the relatedness 
of the plants used for specific therapeutic applications. In test 
4, using null 0, all tips in the phylogeny could be included in the 
null. In test 5, we use null 1 to sample from the medicinal plants 
for any therapeutic application and across all medicinal floras. If 
medicinal plants are themselves clustered, test 4 could be influ-
enced by the overall pattern, whereas test 5 asks whether from 
among the medicinal plants only there is evidence of relatedness. 
NRIi,j=−1×
MPDobserved−MPDrandom
sd(MPDrandom)
,
NTIi,j=−1×
MNTDobserved−MNTDrandom
sd(MNTDrandom)
.
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Test 6 considers shallow, tip-level relatedness between therapeu-
tic applications; for every combination of place and therapeutic 
application, it is tested whether the closest relatives of medicinal 
genera are used significantly more often than in a null sampled 
from all medicinal genera.
3  | RESULTS
The Omani phylogeny (Dataset S1) and combined phylogeny for 
four floras (Dataset S2) are provided as Supporting Information. The 
combined phylogeny reconstructed comprised sequences repre-
senting 2,982 genera in total, 361 to represent Oman (~80% of the 
flora), and for the three original floras Nepal—1,335(>85%); South 
Africa Cape—792 (~80%); New Zealand—494 (>88%). The four 
Phylocom sample files (Dataset S3 to S6), phylocom instructions and 
commands (Dataset S7) and output values from phylocom (Dataset 
S8) are also provided as Supporting Information.
The two literature sources indicated 106 species in 76 genera 
with medicinal use, representing documented use of 17% of the 452 
genera of Oman. Only 12 of the 13 therapeutic applications were 
represented in the Omani data: there were no reports of use for 
Test Phylogeny Metric; Function
Null 
Model
Supplementary data number: 
Sample(s)
Test 1 QUESTION: Is the Omani medicinal flora a phylogenetically clustered subset of the Omani 
flora?
1 Oman Mean pairwise phylogenetic 
distance (MPD); comstruct
0 S3: Sample = all Omani 
medicinal plants
Test 2 QUESTION: Is the Omani medicinal flora a phylogenetically clustered subset of the Omani 
flora?
2 Combined Mean pairwise phylogenetic 
distance (MPD); comstruct
1 S4: Sample 1 = all Omani 
plants; sample 2 = all Omani 
medicinal plants
Test 3 QUESTION: Is the medicinal flora of Oman as a whole is drawn from the same deep lineages as 
the medicinal floras of Nepal, The Cape of South Africa and New Zealand?
3 Combined Mean pairwise phylogenetic 
distance (MPD); comdist
0 S5: Four samples, 
representing each of the 
four local medicinal floras
Test 4 QUESTION: Are the plants used for specific therapeutic applications drawn from the same 
deep lineages, where comparisons include same therapeutic application between floras and different 
therapeutic applications within and between floras
4 Combined Mean pairwise phylogenetic 
distance (MPD); comdist
0 S6: Thirteen therapeutic 
applications from four local 
medicinal florasa 
Test 5 QUESTION: Are the plants used for specific therapeutic applications drawn from the same 
deep lineages, where comparisons include same therapeutic application between floras and different 
therapeutic applications within and between floras
5 Combined Mean pairwise phylogenetic 
distance (MPD); comdist
1 S6: Thirteen therapeutic 
applications from four local 
medicinal florasa 
Test 6 QUESTION: Are medicinal genera for specific therapeutic applications nearest phylogenetic 
neighbours, either from the same therapeutic application between floras or different therapeutic 
applications within and between floras
6 Combined Mean nearest taxon distance 
(MNTD); comdistnt
1 S6: Thirteen therapeutic 
applications from four local 
medicinal florasa 
Note: We carry out six analyses, for different combinations of phylogeny, function, null, and 
sample. For phylogeny, Oman refers to a generic level phylogeny of the native angiosperms of 
Oman, reconstructed using rbcL, and Combined includes generic level sampling to represent four 
local Angiosperm floras, Oman, Nepal, the Cape of South Africa and New Zealand. The functions 
and null models are as described in the Phylocom manual (Webb et al., 2011); samples describe the 
taxonomic composition of “clumps” sensu Webb et al. (2011).
aAlthough there are 52 samples possible, only 51 samples were included, because there were no 
cardiovascular disorder applications for Oman. Comparison of Tests 1 and 2 reveals the effect of a 
phylogeny sampling a local flora and being more inclusive. Comparison of Tests 4 and 5 reveals the 
effect of null models selection with the same phylogeny, function, and sample. 
TA B L E  1   Summary of tests
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cardiovascular disorders. Classification of therapeutic applications 
revealed the largest number of genera was used for skin problems 
(29 genera) and gastro-intestinal disorders (27 genera). The fewest 
genera were used for urinary and dentistry/mouth-related disorders, 
with only one taxon used for each of these therapeutic applications. 
In total, there were 114 combinations of use and therapeutic appli-
cation for the 76 medicinal genera of Oman.
Tests 1 and 2 address the same question, whether the Omani 
medicinal flora is a phylogenetically clustered subset of the Omani 
flora. They differ in the phylogeny used, so comparison of the two 
tests shows the implications of using a local (Test 1) or more inclu-
sive phylogeny and appropriate null (Test 2). Our community phylo-
genetic analysis performed using the Oman phylogeny (Test 1) did 
not reveal significant clustering or overdispersal of medicinal plants 
[NRI = 1.6; MPD.rankLow = 9,467; runs = 9,999, P value > 0.025 
and < 0.975 where significant values are p < .025 (overdispersal) 
and p > .975 (clustering)]. However, our community phylogenetic 
analysis performed using the combined phylogeny (Test 2) revealed 
phylogenetically structured medicinal plants [NRI = 2.5; MPD.rank-
Low = 9,965, runs = 9,999; p value = >.975].
A taxonomic comparison between Oman and the other three 
floras showed the Omani flora and medicinal plants to be most sim-
ilar to those of Nepal (Table 2). Phylogenetically (Test 3), the Omani 
medicinal flora is clustered with the other three medicinal floras (NRI 
values positive and > 1.96; Table 2).
The comparisons between medicinal floras at the generic level 
for the 13 therapeutic applications (Tests 4, 5 and 6) are presented 
in Figure 2 (a-c respectively). Test 4 shows that under null 0, use 
for a therapeutic application in one flora predicts often use for the 
same therapeutic application in other floras. However, similarly high 
levels of cross-predictivity between therapeutic applications at deep 
phylogenetic levels are also revealed (Figure 2a). Using null model 
1 rather than null model zero, so that the null is sampled from the 
medicinal plants rather than the whole phylogeny (the flora), the 
F I G U R E  1   The relationship between null models and sample files for local and combined phylogenies. Test 1: Using null model 0 to test 
the structure of Omani medicinal genera in Omani flora, the Oman flora was all included in the local phylogeny. Test 1A: Local phylogeny 
represent the Oman flora; each orange colour bar indicates the position of medicinal used genus. Test 1B: A part of the sample file used for 
test 1. The first column is the sample, the second is the abundance (in this study it was all set to 1), the third is the species code which should 
be identical with the tip label in the phylogeny. Test 2: Using null model 1 to test the structure of Omani medicinal genera in the combined 
phylogeny. Test 2A: combined phylogeny including Oman flora; each orange colour bar indicates the position of medicinal used genus. Green 
bars indicate genera in the Omani flora. Test 2B: A part of the sample file used for test 2. The first column is the sample, the second is the 
abundance (in this study it was all set to 1), the third is the species code which should be identical with the tip label in the phylogeny. Tree 
figures prepared using iTOL (https://itol.embl.de/itol.cgi)
T
est 1
Test 1A: Local phylogeny
OmanMed 1
OmanMed 1
OmanMed 1
OmanMed 1
OmanMed 1
OmanMed 1
… … …
OmanMed 1 Plumbago
T
est 2 Test 2A: Combined phylogeny Test 2B: Example sample file
OmanMed 1
OmanMed 1… … …
OmanMed 1 Plumbago
OmanFl 1
OmanFl 1
… … …
OmanFl 1 Peperomia
Oman Medicinal used plants
Oman flora
Oman Medicinal used plants 
Test 1B: Example sample file
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frequency of predictivity is strongly reduced (Test 5; Figure 2b). The 
highest frequency of significant clustering is between therapeutic 
applications in Oman, and within and between therapeutic applica-
tions in the comparisons between Oman and Nepal. At tip-levels in 
the phylogeny comparisons between local medicinal floras reveal 
a high frequency of overdispersal, but within local floras there is a 
high frequency of clustering between therapeutic applications (Test 
6; Figure 2c).
4  | DISCUSSION
Phylodiversity metrics, first used in conservation biology then in 
macroecology and community ecology, have become a critical com-
ponent of modern ecology (Tucker et al., 2016). Increasingly com-
plete phylogenetic hypotheses and better understanding of the 
power and reach of the approaches have enabled a diversity of ap-
plications. The development of the field has led to a proliferation 
in phylodiversity metrics, with at least 70 metrics available (Tucker 
et al., 2016). Borrowing the appropriate metric from ecology to ad-
dress questions in a different field demands good understanding of 
the metrics available. Since one of our goals here is to make phy-
logenetic study of medicinal floras more accessible to researchers 
with backgrounds in ethnobotany, we begin here by introducing the 
metrics we have chosen to test our hypotheses.
The metrics we use here are divergence metrics sensu Tucker 
et al. (2016). Divergence metrics are used to measure the overall evo-
lutionarily dissimilarity of samples (in ecological applications referred 
to as groups, assemblages or communities, though we use “sample” 
here to indicate plants chosen for medicinal use). Dissimilarity can be 
calculated for the sample of taxa sampled from a pool, as a measure 
alpha-phylodiversity or community structure. Alpha-phylodiversity 
metrics indicate whether the community sampled from a pool of 
taxa is significantly more clustered, or significantly more dispersed, 
than a random sample of the local species pool. In ecology, signifi-
cant phylogenetic clustering is interpreted as the result of environ-
mental filtering of lineages that possess specialized adaptations to 
counter extreme environments (e.g. Fine & Kemble, 2013). Where 
alpha phylodiversity measures are available for multiple environ-
ments, environments with and without environmental filtering may 
be identified. In ethnobotany, clustering points toward preference 
for specific lineages for medicinal use (Saslis-Lagoudakis et al., 2012; 
Souza, Williamson, & Hawkins, 2018); a metric used in ecology to in-
vestigate environmental filtering is appropriate here since filtering is 
analogous to the selection by people for medicine. Dissimilarity can 
be also calculated between pairs of samples, and we make use of this 
approach too. Comparisons between samples, describing the dissim-
ilarity of pairs of samples, are measuring beta phylodiversity. We 
might imagine an ecological scenario where beta-phylodiversity 
is used as follows: there are multiple mountains for which species 
lists for both low elevation and high elevation sites are available. Is 
any community from high elevation more similar to other high al-
titude communities, or are more similar communities found at low 
and high elevations within mountains? Considering medicinal floras, 
an analogous question might be whether medicinal floras are more 
similar if the people adopting each medicinal flora share more re-
cent ancestry, or if they live in closer proximity to each other and 
can share knowledge (Saslis-Lagoudakis et al., 2014; Teixidor-Toneu 
et al., 2018). Here beta-phylodiversity is considered in the light of 
opportunity for exchange of knowledge and background floristic 
similarity.
Having identified divergence metrics as appropriate for our 
study, we selected Mean Pairwise Phylogenetic Distance (MPD) 
and the related metric Mean Nearest Taxon Distance (MNTD) as our 
metrics of choice. These divergence metrics measure pairwise dis-
tances, using either all pairwise distances for a sample ((MTD, Tests 
1 and 2), or a pair of samples of taxa (MTD, tests 3 to 5, Table 1), or 
the subset of shortest distances between a pair of samples (MNTD, 
Test 6, Table 1). Thus, we apply these divergence methods to assess 
alpha phylodiversity or sample structure (Tests 1 and 2, Table 1), but 
also beta phylodiversity or the dissimilarity between samples (Tests 
3 to 6, Table 1). We choose these metrics because of the simplicity 
of using the same metric for alpha and beta-phylodiversity, and also 
because MPD is an “anchor” metric, one with well-known properties 
that lies at the centre of a constellation of less well-known, similar 
metrics (Tucker et al., 2016).
The study we present here draws out methodological issues. 
Firstly, we investigate whether there is clustering of medicinal plants 
overall, within a local flora. Local phylogenies were used to test for 
clustering of medicinal plants in local floras in the first study of this 
Comparison
Flora
Number of genera shared
Medicinal plants
Number of genera shared
Medicinal plants
NRI values
Oman/Nepal 202 39 (19%) 5.6
Oman/South 
Africa Cape
125 18 (14%) 3.7
Oman/New 
Zealand
56 2 (3.5%) 3.3
Note: For taxonomic comparison, the number of genera shared between Oman and the other 
three floras and number of medicinal genera shared is reported. For phylogenetic comparison 
(Test 3), we report NRI values. NRI values that are positive and > 1.96 are indicative of significant 
phylogenetic clustering. The total numbers of genera in each of the three floras is as follows: 
Oman—361; Nepal—1,335; South Africa Cape—792; New Zealand—494.
TA B L E  2   Taxonomic and phylogenetic 
comparison between Omani, Nepali, 
South African Cape, and New Zealand 
floras and medicinal floras
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kind (Saslis-Lagoudakis et al., 2012). Here, we found differences 
when using more inclusive, combined rather than local phylogenies, 
despite the use of null models to make comparable comparisons 
between the Omani medicinal flora and its whole flora. Significant 
clustering was revealed for Oman only when we used a combined 
phylogeny, this can be attributed solely to the phylogenetic frame-
work. We suggest that it is best practice to use a more inclusive phy-
logeny and appropriate null model as we do in Test 2, rather than 
local phylogenies. In the case of this characterization of the Omani 
medicinal flora in the context of the Omani flora, when the combined 
phylogeny is used the whole flora was included in the sample file and 
the null that draws from the sample file to assemble null communi-
ties was used. A global phylogeny would provide the most robust 
estimate of plant relationships, particularly when considering small 
local floras where local approaches might introduce Long Branch 
Attraction and other topological anomalies (Park, Worthington, & 
Xi, 2018). It may not be possible to generate a fully sampled phy-
logeny using published and new sequence data to reconstruct the 
phylogeny. An alternative to building bespoke phylogenies from 
sequence data is to use existing mega-trees and to insert missing 
species or genera at the nodes shared with their closest taxonomic 
relatives (Jin & Qian, 2019). An advantage of the latter approach is 
that the mega-trees are reconstructed from sequence data repre-
senting multiple gene regions, whereas the phylogenies we use here 
are reconstructed using just one gene region, rbcL. We follow Park 
et al.’s (2018) recommendation for community phylogenetics that an 
F I G U R E  2   Cross-cultural tests of relatedness of therapeutic applications. Heat maps show clustering (green) and overdispersal (red) 
for all pairs of comparisons. Comparisons are for the four cultures, Nepal (grey), the Cape of South Africa (yellow), New Zealand (blue), 
and Oman (orange). The blocks of the heatmap are as follows: block A for test 4, using comdist and null model 0; block B for test 5 using 
comdist and null model 1; block C for test 6 using comdistnt and null model 1. Block A is mostly green (significantly similar lineages) with 
no red (significantly different lineages). There are some parts of block A where almost all cells are green, for example, comparing different 
therapeutic applications within Nepal. There are some parts of block A where few cells are green, for example comparing different 
therapeutic applications within Cape of South Africa. In this case any plant present in the phylogeny can be included in the null, and the 
large number of green cells points to lineages that, relative to plants as a whole, are used for multiple therapeutic applications. Block B has 
many green cells (clustering) for comparisons between therapeutic applications within Nepal, also within Oman, and for many Nepal-Oman 
comparisons. Green cells are few between other pairs of cultures, and there is overdispersal for some therapeutic applications. Since the 
null is sampled from medicinal plants, the effect of the overall clustering of medicinal plants is removed and there is much less evidence of 
the same lineages used for different therapeutic applications than is apparent in block A. Block C has only has green cells when within-flora 
comparisons are made. Many comparisons between floras show overdispersal (red cells). The closest relative of a genus with any medicinal 
use is most likely found in the flora in which that genus is found, regardless of therapeutic application. The effect of floristic composition is 
strong when investigating tip-level relationships
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effort should be made to generate a better phylogeny at least by 
including non-local taxa as placeholders.
Secondly, we highlight the importance of choice of null model in 
cross-cultural analysis. Null model 0 is used to test whether plants 
of one medicinal flora are clustered with those of another, where 
the null is drawn from the whole phylogeny. Null model 1 is used 
to test whether, from within the sample of medicinal plants, plants 
of one medicinal flora are clustered with those of another. The se-
lection of the null model therefore frames the question as well as 
influencing the results. Here, we used null 0 to test whether a pair of 
therapeutic applications is a phylogenetically structured subset of all 
plants. We found many were more closely related than expected by 
chance (Figure 2a), consistent with the findings of the previous study 
that we extend here (Saslis-Lagoudakis et al., 2012). However, when 
we tested whether a pair of therapeutic applications are a phylo-
genetically structured subset of the medicinal plants there was less 
evidence of relatedness. When considering therapeutic applications 
under null 0, it is not surprising that so many therapeutic applications 
are clustered, since we know that medicinal plants overall are clus-
tered (Table 2). By selecting null model 1, we remove the influence 
of the relatedness of medicinal plants overall, allowing more criti-
cal evaluation of how different therapeutic application behave. Null 
model 0, because of the strong influence of relatedness of medicinal 
plants overall, recovers spurious similarity attributed to plants for 
specific therapeutic applications being a subset of the phylogenet-
ically clustered medicinal plants. Using the more conservative null, 
we show that aside from the Nepal—Oman comparison, there is little 
evidence that people in different localities are using the same lin-
eages of plants for the same therapeutic applications.
A third important finding related to methodological approach, 
and with implications for interpretation of findings, is that therapeu-
tic applications within cultures are often cross-predictive. In other 
words, we find that the same plant lineages are used for different 
therapeutic applications. We found many cases of cross-predictivity 
for therapeutic applications in Nepal and in Oman, the largest and 
smallest medicinal floras respectively. Cross-predictivity was rare 
for Cape of South Africa (under null 0 and 1) and New Zealand (under 
null model 1). Cross-predictivity might be attributed to plants with 
shared bioactivity finding use for different therapeutic applications, 
as might be expected if for example many therapeutic applications 
of plants depend on anti-inflammatory properties (Ernst et al., 2016; 
Saslis-Lagoudakis, Klitgaard, et al., 2011) or other properties such 
as antibiotic properties. Cross-predictivity suggests that targeting 
plants for screening based on their specific therapeutic applications, 
in order to identify lead compounds with properties relevant to that 
specific application, may not be an effective approach. Reverse 
ethnopharmacology has shown few positive associations between 
the clinical use of proven bioactives and traditional therapeutic ap-
plications, and that cross-over relationships where traditional use 
and biomedical therapeutics point to different applications is more 
numerous (Leonti et al., 2017). In this context, it might be more in-
teresting when different lineages are used for different therapeutic 
applications, as evidenced by overdispersal between therapeutic 
applications. For example, Souza et al. (2018) found that plants used 
by women represented different phylogenetic lineages of Brazilian 
Leguminosae. Reverse ethnopharmacology highlighted an associa-
tion between plants used by women and anticancer drugs (Leonti 
et al., 2017); Souza et al. (2018) suggested that the drugs used by 
women included plants of strong effect used to terminate unwanted 
pregnancies. Plants of strong effect might be expected to appear 
in different lineages to the more frequently used and often inter-
changeable plants of mild effect. We find some overdispersal under 
null 1 in the case of a few therapeutic applications, including use 
for dentistry/mouth in New Zealand (19 genera), and for urinary 
complaints in the Cape of South Africa (45 genera). Why different 
lineages are used for different therapeutic applications in these 
two local medicinal floras, but not in Oman or Nepal, could be in-
vestigated further. One hypothesis to test is that cross-predictiv-
ity is associated with humoral medicine, the shared beliefs about 
illness causation found in Oman and Nepal (Durkin-Longley, 1984; 
Ghazanfar & Al-Sabahi, 1993).
Our final test, using the comdistnt measure of nearest taxon 
distance, investigated relatedness of plants with different specific 
therapeutic applications within or between areas, or with different 
therapeutic applications within an area. We showed that the closest 
relative of a medicinal plant with a specific therapeutic application 
in an area is mostly likely found within that same area. This was true 
for all four medicinal floras. This may reflect the structure of the 
combined phylogeny at tip level (sister genera would be expected 
to be found within floras). The genera of the Cape of South Africa 
have the strongest pattern of tip-relatedness, as might be expected 
since it comprises a Floral Kingdom composed of many radiating or 
endemic taxa. Oman has the fewest instances of closest relatives 
within Oman. This could be due to the low number of reports for 
Oman: in total there were 114 combinations of use and application 
for 76 medicinal genera, compared to 1872 for the 563 medici-
nal genera of Nepal, 896 for the 198 medicinal genera of Cape of 
South Africa and 416 for the medicinal 97 genera of New Zealand. 
Generally, deeper measures of relatedness are more informative 
in studies of medicinal plant use. Preferences for lineages at deep 
levels can be associated with shared bioactivity (Saslis-Lagoudakis 
et al., 2012; Zhu et al., 2011).
There are three methodological issues that we do not explicitly 
explore here: the completeness of sampling, the hierarchical level of 
sampling, and the rate-smoothing approach taken. Considering com-
pleteness of sampling, in the case of Oman and Cape of South Africa 
our phylogenies include approximately 80% of the genera found the 
local flora, and our best represented flora is New Zealand with more 
than 88% of genera in the phylogeny. Although Tests 1 and 2 explore 
taxon sampling effects due to the use of local versus more inclu-
sive phylogenies, we did not consider the effects of missing genera. 
Others have explored this, for example Jantzen et al. (2019) made a 
test of the effects of taxon sampling on phylodiversity metrics. They 
showed that sampling higher proportions of local species increases 
the likelihood of finding significant phylogenetic patterns when they 
exist. Jantzen et al. (2019) caution that, for small or undersampled 
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communities, there may not be enough statistical power to detect 
nonrandom patterns even when they may exist in nature. The tests 
in our study which did not reveal significant clustering but for which 
some values were close to the threshold for significance were tests 
4, 5, and 6, tests which examined smaller samples because they 
consider the subsets of genera used for specific therapeutic appli-
cations. There might be more significant relationships between pairs 
of therapeutic applications if we had more complete sampling, more 
frequent reporting of phylogenetic structure. This would not refute 
our most important finding with respect to therapeutic applications, 
that there is a great deal of cross-predictivity between therapeu-
tic applications. Nor would we expect that the patterns revealed by 
Test 6 to change, we would still expect that most often the closest 
relatives of medicinal genera are found in the same flora.
The second methodological issue not explored here relates to 
the hierarchical level of sampling. Whether, and if so when, it is more 
appropriate to use species-level phylogenies should be the focus 
of future study. In reconstructing the phylogeny and in scoring the 
presence or absence of plant use at the generic level, we follow the 
study that we extend here (Saslis-Lagoudakis et al., 2012). To date, 
published studies using species-level phylogeny to explore medici-
nal plant use are generally limited to studies of genera (e.g. Saslis-
Lagoudakis, Klitgaard, et al., 2011; Ernst et al., 2016, but see Souza 
et al., 2018). We expect that generic level is most appropriate if the 
study includes all flowering plants and calculates NRI, as ours does. 
This is because NRI values describe a deep relationship in the phy-
logeny, and generic-level data could provide evidence for cluster-
ing of interest at tribal or sub familial levels. If the study is directed 
toward understanding tip-level, shallow relationships these might 
be best investigated in a species-level study of a genus of family. 
The phenomenon of generic complexes, where different scientific 
species with the same vernacular name are used interchangeably, is 
well known in ethnobotany (Linares & Bye, 1987). Although generic 
complexes may include unrelated species, the prevalence of use of 
clusters of close relatives and dispersed deep linages might contrib-
ute to a pattern of overdispersed clusters when species-level analy-
ses are performed (Souza et al., 2018). Ultimately, calculating metrics 
for phylogenies at family, genus and species levels might reveal test 
whether patterns recovered are caused by the concentration of use-
ful species in particular taxonomic units.
The third methodological issue not explored here relates to 
rate-smoothing or time calibration of the phylogeny used. Our anal-
yses were performed on a rate-smoothed but not time-calibrated 
phylogeny. The community phylogenetics literature includes met-
rics calculated using phylograms and chronograms (Li et al., 2019). 
This choice can lead to significantly different results in some cases 
(Allen et al., 2019; Jantzen et al., 2019; Li et al., 2019). We found rate 
smoothing to reduce the strong effect of taxa on long branches, and 
we considered this desirable, especially when some samples are small.
A final consideration is whether there should be an adjustment 
to the threshold for significance when many tests are carried out, as 
is the case here. The Bonferroni correction is sometimes used to ad-
just the alpha threshold for each comparison, so that the study-wide 
error rate remains at 0.05 (Cabin & Mitchell, 2000). The correction 
provides a conservative estimate of significance, minimizing type 
I errors but inflating type II errors. Saslis-Lagoudakis et al. (2012) 
highlighted results remaining significant after Bonferroni correction 
in their results tables. This approach has the advantage of allowing 
the reader to decide what is worse, false positives or negatives, 
when considering individual values. However, where the interest 
is in overall pattern rather than individual comparisons as is the 
case with the heat map presented here (Figure 2), we argue against 
Bonferroni correction.
Whether different people share preferences for medicinal plants 
is a question that has been addressed many times, using different 
methods applied at different spatial scales and at different taxo-
nomic levels. Since independent discovery of plant properties is 
considered to point toward efficacy (Bletter, 2007; Moerman, 2007; 
Trotter & Logan, 1986), discovering shared preferences may be in-
formative (Saslis-Lagoudakis et al., 2012). Here, our approach is 
phylogenetic, and we consider distantly related cultures exposed to 
very different floristic environments. By showing significant phylo-
genetic clustering of medicinal genera between cultures, we demon-
strate that Omani medicinal use of plants emphasizes the same deep 
lineages of flowering plants as the Nepalese, South African Cape 
and Māori uses. This finding points toward a global pattern of pre-
ferred plant uses, relevant to the interpretation of the pre-history of 
human–plant interactions and the history of medicine.
Phylogenetic investigation of whole medicinal floras opens 
up several lines of research. One depends on the identification of 
“hot nodes”, nodes on the phylogeny that include significantly more 
plants traditionally used in medicine (Saslis-Lagoudakis, Klitgaard, 
et al., 2011; Saslis-Lagoudakis et al., 2012). These hot node methods 
allow the taxa belonging to lineages used more than expected to 
be enumerated. How these hot node methods might be applied in 
bioprospecting is a matter of ongoing research (Souza et al., 2018). 
Another approach depends on the spatial mapping of phylogenetic 
diversity (PD), a diversity measure predictive of feature diversity 
that can have conservation applications (Faith, 1992; Forest et al., 
2007). Neither hot node nor PD mapping approaches are applied 
here. Instead, in this study we use cross-cultural comparisons that 
are directed toward better understanding of the cultural factors un-
derlying the use of plants as medicines. For example, it is possible 
to evaluate whether relatedness of medicinal floras is predicted by 
relatedness of floras as would be the case when plants from the local 
environment are selected in the absence of significant alternative 
drivers of plant selection, such as cultural ancestry or migration his-
tory. The influence of cultural ancestry has been investigated (Saslis-
Lagoudakis et al., 2014; Thompson et al., unpublished). However, 
although it has been proposed that plant preferences could reflect 
migration history, rather than the current floristic environment in 
which people are currently settled (Leonti et al., 2003; Moerman 
et al., 1999), this hypothesis has not been tested phylogenetically. In 
the present study, we find the Omani medicinal flora is most similar 
to the Nepalese one. One driver of this relationship could be floristic 
environment since we also find that the Omani flora is also more 
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similar taxonomically to the Nepalese flora than to any of the other 
floras considered. That the flora—a proxy for plant availability—is the 
main determinant of plant use in our study, was also revealed by an-
other phylogenetic study (Saslis-Lagoudakis, Klitgaard, et al., 2011). 
Secondly, other drivers of relatedness of medicinal floras can be ex-
plored. These could include shared beliefs about illness causation, 
use of a shared scholarly medical system, or transmission of tradi-
tional knowledge of plants. Cultural contact between Nepal and 
Oman would be expected to be greater than contact between Oman 
and the other cultures in our study, through the movement of people 
and ideas. Oman was an important medieval trading post with many 
products entering its ports, including Indian plant drugs also im-
portant in Nepal (Amar & Lev, 2017). In terms of beliefs, the Galenic 
humoral system found in northern and central Oman (Ghazanfar & 
Al-Sabahi, 1993) also contributes to Nepalese practice through his-
torical regional (Yoeli-Tlalim, 2013) and modern local pluralistic plant 
medicine (Durkin-Longley, 1984).
Were a wider set of medicinal floras under investigation, it would 
be possible to account for Galton's problem - that relatedness ac-
counts for cross-cultural similarity - and formally test the extent to 
which overall similarity in composition of medicinal floras was due to 
present geographic proximity (as a proxy for the likelihood of knowl-
edge exchange through cultural diffusion), health needs or theory 
of disease causation (Teixidor-Toneu et al., 2018). Whether the folk 
knowledge of Oman and Nepal reflect the influences of transmission 
of knowledge could also be tested further by focusing on the plant 
names, therapeutic applications, and plant parts used at species 
level for shared species, using phylogenetic comparative methods 
and ethnolinguistic phylogenies. An approach of this kind could also 
tease apart Tibeto-Burman and Eurasian influences on the medicinal 
flora of Nepal. Our study represents a step toward using a global 
phylogeny and a global estimate of the relatedness of cultures, using 
macro-evolutionary methods.
5  | CONCLUSION
Phylogenetic methods are a powerful tool to better understand me-
dicinal plant use. Here, we focus on cross-cultural patterns in the 
use of medicinal plants. We show that a more inclusive phylogeny 
of plants provides an optimal framework, as long as appropriate null 
models are selected. We highlight the best practice for cross-cultural 
study, particularly in the interpretation of shared therapeutic appli-
cations. We contribute to the emerging picture of the same plant 
lineages being used for multiple therapeutic applications. The first 
study to use a phylogeny of plants to explore cross-cultural pat-
terns at the level of whole medicinal floras, in the way we do here, 
identified lineages that were putatively independently discovered 
(Saslis-Lagoudakis et al., 2012). Here, we incorporate the medicinal 
flora of a cultures likely to have had opportunity for transmission 
of traditional knowledge with another, if not directly then through 
multiple intermediaries across wide distances. Ultimatel, we may be 
able to identify drivers of overall similarity in medicinal floras using 
the methods outlined here, alongside those of evolutionary anthro-
pology (Teixidor-Toneu et al., 2018). Including cultures with more 
or less similar floras, health needs, theories of disease causation, 
and opportunity for knowledge exchange, we can more rigorously 
test the hypothesis that lineages were independently discovered 
by identifying factors contributing to knowledge transfer (Teixidor-
Toneu et al., 2018). Interdisciplinary study combining plant phylog-
enies, evolutionary anthropology, and ethnobotanical data have 
great promise, but only if methods are robust (Hawkins & Teixidor-
Toneu, 2017); here, we take steps to promote these methods.
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